An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold S… (NCT05796635) | Clinical Trial Compass
CompletedNot Applicable
An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores
United States80 participantsStarted 2023-01-04
Plain-language summary
Focus Consumer Healthcare has developed Herpecin L. Herpecin L combines many different ingredients hypothesized to promote quick healing and symptom reduction from cold sores.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male Female between 18-60 years of age.
* Must be in good health with no significant chronic conditions and a BMI under 35.
* Must experience regular cold sores or fever blisters
* Must agree to avoid daily lip balm or another product designed to alleviate their cold sore (e.g., Abreva or other over-the-counter cold sore products).
Exclusion Criteria:
* Suffers from pre-existing conditions that would prevent them from adhering to the protocol including chronic conditions such as oncological or psychiatric disorders.
* Anyone with known severe allergic reactions.
* Unwilling to follow the study protocol.
* Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study.
What they're measuring
1
The primary aim of this research is to understand the changes in cold sore severity.